世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
Tumor Necrosis Factor Inhibitor Drugs Market Size, Share & Trends Analysis Report By Product (Humira, Enbrel Remicade, Simponi/Simponi Aria, Cimzia), By Application, By Sales Channel, By Region, And Segment Forecasts, 2025 - 2030
Tumor Necrosis Factor Inhibitor Drugs Market Growth & Trends The global tumor necrosis factor inhibitor drugs market size is estimated to reach USD 26.6 billion by 2030, registering a CAGR of 2.... もっと見る
SummaryTumor Necrosis Factor Inhibitor Drugs Market Growth & TrendsThe global tumor necrosis factor inhibitor drugs market size is estimated to reach USD 26.6 billion by 2030, registering a CAGR of 2.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of autoimmune diseases, rapid technological advancements, and rise in healthcare expenditure across the globe are some of the major factors expected to drive the growth. Currently, there are five approved TNF inhibitor drugs in the market- Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Simponi/Simponi Aria (golimumab), and Cimzia (certolizumab). Biosimilar versions of Humira, Enbrel, and Remicade have been launched, causing a significant paradigm shift in the market. The wave of biosimilars pose a significant internal threat to the biologics sale as biosimilars have a comparable efficiency as the original products. The cost-effectiveness of biosimilars makes them an attractive choice in economically sensitive areas. In addition, emerging countries, such as India, China, and South Korea are active participants in the biosimilar market. Some of the key therapeutic areas involving treatment with TNF inhibitor drugs are rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Although these medicines are mostly used for the treatment of autoimmune diseases, several ongoing studies are investigating the role of TNF inhibitors in the treatment of cancer and other inflammatory conditions. Some of the key players in the TNF inhibitor space are involved in strategic initiatives, such as mergers and acquisitions and joint ventures for the co-development of products. In addition, patent infringement issues between the manufacturers makes the market dynamics intensely competitive. For instance, AbbVie resolved an issue with Boehringer Ingelheim, regarding Humira’s intellectual property (IP) rights. As per the terms of the agreement, Boehringer Ingelheim received a non-exclusive license to Humira’s IP in the U.S.- scheduled to begin in July 2023. Tumor Necrosis Factor Inhibitor Drugs Market Report Highlights • By product, the humira segment dominating the market with the largest revenue share of 40.5% in 2024, due to its proven effectiveness in treating various autoimmune disorders, which fostered strong trust among patients and healthcare providers. • In 2024, Rheumatoid arthritis dominated the market and accounted for the largest revenue share of 17.51%, due to its high prevalence globally. • The online pharmacy is expected to grow at the highest CAGR over the forecasted period, due to easy access to digital platforms, smooth ordering, in time delivery, and affordable pricing. Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation and Scope 1.2. Market Definitions 1.3. Research Methodology 1.3.1. Information Procurement 1.3.2. Information or Data Analysis 1.3.3. Market Formulation & Data Visualization 1.3.4. Data Validation & Publishing 1.4. Research Scope and Assumptions 1.4.1. List of Data Sources Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.3. Competitive Insights Chapter 3. Tumor Necrosis Factor Inhibitor Drugs Market Variables, Trends, & Scope 3.1. Market Introduction/Lineage Outlook 3.2. Market Size and Growth Prospects (USD Million) 3.3. Market Dynamics 3.3.1. Market Drivers Analysis 3.3.2. Market Restraints Analysis 3.4. Tumor Necrosis Factor Inhibitor Drugs Market Analysis Tools 3.4.1. Porter’s Analysis 3.4.1.1. Bargaining power of the suppliers 3.4.1.2. Bargaining power of the buyers 3.4.1.3. Threats of substitution 3.4.1.4. Threats from new entrants 3.4.1.5. Competitive rivalry 3.4.2. PESTEL Analysis 3.4.2.1. Political landscape 3.4.2.2. Economic and Social landscape 3.4.2.3. Technological landscape 3.4.2.4. Environmental landscape 3.4.2.5. Legal landscape Chapter 4. Tumor Necrosis Factor Inhibitor Drugs Market: Product Estimates & Trend Analysis 4.1. Type Market Share, 2024 & 2030 4.2. Type Segment Dashboard 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million) 4.4. Humira 4.4.1. Humira Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 4.5. Enbrel 4.5.1. Enbrel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 4.6. Remicade 4.6.1 Remicade Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 4.7. Simponi/Simponi Aria 4.7.1 Simponi/Simponi Aria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 4.8. Cimzia 4.8.1 Cimzia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 4.9. Biosimilars 4.9.1 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Chapter 5. Tumor Necrosis Factor Inhibitor Drugs Market: Application Estimates & Trend Analysis 5.1. Application Market Share, 2024 & 2030 5.2. Application Segment Dashboard 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million) 5.4. Rheumatoid Arthritis 5.4.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.5. Psoriasis 5.5.1. Psoriasis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.6. Psoriatic Arthritis 5.6.1. Psoriatic Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.7. Crohn’s Disease 5.7.1. Crohn’s Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.8. Ulcerative Colitis 5.9. Ulcerative Colitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Psoriatic Arthritis 5.10. Ankylosing Spondylitis 5.10.1. Ankylosing Spondylitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.11. Juvenile Idiopathic Arthritis 5.11.1. Juvenile Idiopathic Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.12. Hidradenitis suppurativa 5.12.1. Hidradenitis suppurativa Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 5.13. Others 5.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Chapter 6. Tumor Necrosis Factor Inhibitor Drugs Market: Sales Channel Estimates & Trend Analysis 6.1. Sales Channel Market Share, 2024 & 2030 6.2. Sales Channel Segment Dashboard 6.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million) 6.4. Hospital Pharmacy 6.4.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 6.5. Speciality Pharmacy 6.5.1. Speciality Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) 6.6. Online Pharmacy 6.6.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million) Chapter 7. Tumor Necrosis Factor Inhibitor Drugs Market: Regional Estimates & Trend Analysis 7.1. Regional Market Share Analysis, 2024 & 2030 7.2. Regional Market Dashboard 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030: 7.4. North America 7.4.1. North America Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.4.2. U.S. 7.4.2.1. Key Country Dynamics 7.4.2.2. Regulatory Framework 7.4.2.3. Competitive Insights 7.4.2.4. U.S. Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.4.3. Canada 7.4.3.1. Key Country Dynamics 7.4.3.2. Regulatory Framework 7.4.3.3. Competitive Insights 7.4.3.4. Canada Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.4.4. Mexico 7.4.4.1. Key Country Dynamics 7.4.4.2. Regulatory Framework 7.4.4.3. Competitive Insights 7.4.4.4. Mexico Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.5. Europe 7.5.1. Europe Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.5.2. UK 7.5.2.1. Key Country Dynamics 7.5.2.2. Regulatory Framework 7.5.2.3. Competitive Insights 7.5.2.4. UK Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.5.3. Germany 7.5.3.1. Key Country Dynamics 7.5.3.2. Regulatory Framework 7.5.3.3. Competitive Insights 7.5.3.4. Germany Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.5.4. France 7.5.4.1. Key Country Dynamics 7.5.4.2. Regulatory Framework 7.5.4.3. Competitive Insights 7.5.4.4. France Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.5.5. Italy 7.5.5.1. Key Country Dynamics 7.5.5.2. Regulatory Framework 7.5.5.3. Competitive Insights 7.5.5.4. Italy Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.5.6. Spain 7.5.6.1. Key Country Dynamics 7.5.6.2. Regulatory Framework 7.5.6.3. Competitive Insights 7.5.6.4. Spain Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.5.7. Denmark 7.5.7.1. Key Country Dynamics 7.5.7.2. Regulatory Framework 7.5.7.3. Competitive Insights 7.5.7.4. Denmark Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.5.8. Sweden 7.5.8.1. Key Country Dynamics 7.5.8.2. Regulatory Framework 7.5.8.3. Competitive Insights 7.5.8.4. Sweden Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.5.9. Norway 7.5.9.1. Key Country Dynamics 7.5.9.2. Regulatory Framework 7.5.9.3. Competitive Insights 7.5.9.4. Norway Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.6. Asia Pacific 7.6.1. Asia Pacific Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.6.2. China 7.6.2.1. Key Country Dynamics 7.6.2.2. Regulatory Framework 7.6.2.3. Competitive Insights 7.6.2.4. China Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.6.3. Japan 7.6.3.1. Key Country Dynamics 7.6.3.2. Regulatory Framework 7.6.3.3. Competitive Insights 7.6.3.4. Japan Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.6.4. India 7.6.4.1. Key Country Dynamics 7.6.4.2. Regulatory Framework 7.6.4.3. Competitive Insights 7.6.4.4. India Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.6.5. South Korea 7.6.5.1. Key Country Dynamics 7.6.5.2. Regulatory Framework 7.6.5.3. Competitive Insights 7.6.5.4. South Korea Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.6.6. Australia 7.6.6.1. Key Country Dynamics 7.6.6.2. Regulatory Framework 7.6.6.3. Competitive Insights 7.6.6.4. Australia Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.6.7. Thailand 7.6.7.1. Key Country Dynamics 7.6.7.2. Regulatory Framework 7.6.7.3. Competitive Insights 7.6.7.4. Thailand Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.7. Latin America 7.7.1. Latin America Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.7.2. Brazil 7.7.2.1. Key Country Dynamics 7.7.2.2. Regulatory Framework 7.7.2.3. Competitive Insights 7.7.2.4. Brazil Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.7.3. Argentina 7.7.3.1. Key Country Dynamics 7.7.3.2. Regulatory Framework 7.7.3.3. Competitive Insights 7.7.3.4. Argentina Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.8. Middle East and Africa 7.8.1. Middle East and Africa Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.8.2. South Africa 7.8.2.1. Key Country Dynamics 7.8.2.2. Regulatory Framework 7.8.2.3. Competitive Insights 7.8.2.4. South Africa Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.8.3. Saudi Arabia 7.8.3.1. Key Country Dynamics 7.8.3.2. Regulatory Framework 7.8.3.3. Competitive Insights 7.8.3.4. Saudi Arabia Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) 7.8.4. UAE 7.8.4.1. Key Country Dynamics 7.8.4.2. Regulatory Framework 7.8.4.3. Competitive Insights 7.8.4.4. UAE Tumor Necrosis Factor Inhibitor Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Participant Overview 8.2. Company Market Position Analysis 8.3. Company Categorization 8.4. Strategy Mapping 8.5. Company Profiles/Listing 8.5.1. AbbVie, Inc. 8.5.1.1. Participant’s Overview 8.5.1.2. Financial Performance 8.5.1.3. Product Benchmarking 8.5.1.4. Recent Developments/ Strategic Initiatives 8.5.2. Amgen, Inc. 8.5.2.1. Participant’s Overview 8.5.2.2. Financial Performance 8.5.2.3. Product Benchmarking 8.5.2.4. Recent Developments/ Strategic Initiatives 8.5.3. Johnson & Johnson Services, Inc. 8.5.3.1. Participant’s Overview 8.5.3.2. Financial Performance 8.5.3.3. Product Benchmarking 8.5.3.4. Recent Developments/ Strategic Initiatives 8.5.4. UCB S.A. 8.5.4.1. Participant’s Overview 8.5.4.2. Financial Performance 8.5.4.3. Product Benchmarking 8.5.4.4. Recent Developments/ Strategic Initiatives 8.5.5. Pfizer, Inc. 8.5.5.1. Participant’s Overview 8.5.5.2. Financial Performance 8.5.5.3. Product Benchmarking 8.5.5.4. Recent Developments/ Strategic Initiatives 8.5.6. Novartis International AG 8.5.6.1. Participant’s Overview 8.5.6.2. Financial Performance 8.5.6.3. Product Benchmarking 8.5.6.4. Recent Developments/ Strategic Initiatives 8.5.7. Boehringer Ingelheim Pharmaceuticals, Inc. 8.5.7.1. Participant’s Overview 8.5.7.2. Financial Performance 8.5.7.3. Product Benchmarking 8.5.7.4. Recent Developments/ Strategic Initiatives 8.5.8. Merck & Co., Inc. 8.5.8.1. Participant’s Overview 8.5.8.2. Financial Performance 8.5.8.3. Product Benchmarking 8.5.8.4. Recent Developments/ Strategic Initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
Grand View Research社の医薬品分野での最新刊レポート
本レポートと同じKEY WORD（inhibitor）の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ（Grand View Research）は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/12 10:26 153.40 円 161.58 円 198.54 円 |
